Clinical Trial

Reprometabolic Syndrome Mediates Subfertility in Obesity

Study Description

Reprometabolic Syndrome Mediates Subfertility in Obesity

Obesity plays an adverse role at every stage of conception and pregnancy and mounting evidence implicates relative hypogonadotropic hypogonadism, and reduced menstrual cycle hormone secretion as likely contributors to the subfertility phenotype and possible contributors to complications of pregnancy and the developmental origin of adult diseases such as diabetes and cardiovascular disease. This study will be the first comprehensive investigation to tie together the patterns of hyperinsulinemia, hyperlipidemia and inflammation, characteristic of obesity and obesity-caused relative hypogonadotropic hypogonadotropism and its potential adverse reproductive outcomes. The investigators findings will be used to inform a subsequent clinical intervention to optimize reproductive outcomes for obese women and their offspring.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Insulin

Drug - Intralipid

Drug - Dextrose

Drug - Heparin

Drug - GnRH

Procedure - Hyperinsulinemic Euglycemic Clamp

Additional Information

Official Study Title

Reprometabolic Syndrome Mediates Subfertility in Obesity

Clinical Trial ID

NCT02653092

ParticipAid ID

QdJWye